News | April 07, 2015

WMIS to Collaborate with NCI on Expansion of Co-Clinical Trials

WMIS hails President Obama’s emphasis on precision medicine and expansion of research to speed discovery

April 7, 2015 — The World Molecular Imaging Society (WMIS) announced the kick-off of a collaboration with the National Cancer Institute (NCI) to promote best practices for co-clinical trials. The goal of the collaboration is to speed the discovery of more and better treatments for cancer and other diseases. NCI is part of the National Institutes of Health (NIH).

WMIS also lauded President Obama’s recent announcement of the Precision Medicine Initiative designed “to bring us closer to curing diseases like cancer and diabetes?—?and to give all of us access to the personalized information we need to keep ourselves and our families healthier,” stated Jason Lewis, M.D., professor and vice chair for research, Emily Tow Jackson Chair at Memorial Sloan-Kettering Cancer Center, and president of the WMIS.

Over the past two years, WMIS and the American Association of Physicists in Medicine (AAPM) have shared their interest with NCI to promote best practices for co-clinical trials. The organizations met at the World Molecular Imaging Congress in September 2014 to finalize an agreement that WMIS, with the assistance of the AAPM, would explore how to promote best practice for quantitative imaging for co-clinical trials.

Co-clinical trials are defined as parallel or sequential trials of combination therapy in patients and in mouse and human-in-mouse models of appropriate genotypes to represent the patients. The initiative is designed to help establish best practices for quantitative imaging methods and imaging protocols that are applied to both mouse and human-in-mouse models. The research resources are expected to improve the correlation of results from mouse models with prospective and/or retrospective clinical trial data. The clinical goals are to support effective mouse/human co-clinic therapy and prevention trials.

Molecular imaging and the emerging field of theranostics are essential to the successful implementation of precision medicine. The World Molecular Imaging Society, with its international forum for discussing all aspects of molecular imaging and related fields, is in a unique position to take the lead in global discussion, innovation and scientific collaboration, from preclinical studies to first-in-human imaging trials,” said Hedvig Hricak M.D., Ph.D., chairman, Department of Radiology, Memorial Sloan-Kettering Cancer, and member of WMIS.

As part of the agreement, WMIS will include two spotlight sessions on precision medicine and co-clinical trials during the upcoming 8th Annual World Molecular Imaging Congress. The theme of the meeting is “Precision Medicine, Visualized,” which embodies current and future roles of molecular imaging in basic science, translational medicine and healthcare. The WMIC meeting will take place Sept. 2-5, 2015, in Honolulu, Hawaii.

“The WMIS is committed to bringing key technologies that enable the study of biology in the complexity of living systems to the greater scientific community, and to advancing the imaging tools that will help patients who suffer from the most devastating diseases. Our key focus for 2015 is precision medicine and disseminating knowledge, new tools and technologies that help expand the development of this theme on a global scale is the aim of WMIS and we work with our international colleagues to ensure that our voice reflects the advances taking place around the world,” added Lewis.

For more information: www.wmis.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...